How long does it take to see the effect of Evantumumab/Carestream?

Amivantamab (amivantamab) is a bispecific antibody drug that can simultaneously bind to EGFR and MET to block signal transduction, thereby inhibiting the proliferation and metastasis of tumor cells. The question that many patients are most concerned about before taking medication is: How long will it take to see the effect? In fact, the time it takes for a drug to work varies from individual to individual. Generally speaking, some patients may observe tumor shrinkage or symptom relief on imaging within a few weeks of treatment for non-small cell lung cancer, while other patients may take longer to show a stable response.

This difference is related to a variety of factors. The first is the genetic characteristics of the patient, such as the different types of EGFR exon 20 insertion mutations, which may affect the drug binding efficiency and thus determine the speed of efficacy. The second is the patient's tumor burden. If the disease burden is heavy and the symptoms are obvious, more courses of treatment may be needed to see significant improvement. In addition, whether it is used in combination with other drugs is also an important factor. Studies have shown that when evantuzumab is combined with drugs such as lazertinib, carboplatin or pemetrexed, some patients can achieve faster disease control in a shorter period of time.

It should be noted that evantumumab, as a targeted monoclonal antibody, has a different mechanism of action from traditional chemotherapy. It does not immediately kill cancer cells, but gradually inhibits tumor progression by blocking key signals. Therefore, patients should not rush for results during medication, but should follow the doctor's instructions and conduct regular imaging examinations and laboratory indicator monitoring to comprehensively evaluate the efficacy. In some cases, even if patients do not experience rapid relief of symptoms, drugs may still play a role in maintaining disease stability, which is an important indicator of treatment effectiveness.

Overall, the efficacy of evantumumab is a gradual process and is usually gradually revealed during continued treatment. For patients, adhering to regular medication, waiting patiently, and actively cooperating with doctors for follow-up visits are important prerequisites for ensuring curative effect.

Reference materials:https://www.rybrevant.com/